Researchers in the Netherlands have developed 3D-printed 'mini tumours' that behave like real cancerous tissue and can be used to test new treatments, including drug and cell-based immunoth
The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category
AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.
AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.
Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.